9MKN image
Deposition Date 2024-12-17
Release Date 2025-10-29
Last Version Date 2025-11-19
Entry Detail
PDB ID:
9MKN
Title:
Structure of the Respiratory Syncytial Virus Fusion Protein Bound to Human Antibodies RSV_2245 and RSV_3301
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.40 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F2
Gene (Uniprot):F
Chain IDs:A, C, E
Chain Length:70
Number of Molecules:3
Biological Source:Respiratory syncytial virus
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F1
Gene (Uniprot):F
Mutagens:I379V, M447V variant
Chain IDs:B, D, F
Chain Length:370
Number of Molecules:3
Biological Source:Respiratory syncytial virus
Polymer Type:polypeptide(L)
Molecule:2245 Fab Heavy Chain
Chain IDs:G (auth: H), H (auth: I), I (auth: J)
Chain Length:226
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:2245 Fab Light Chain
Chain IDs:J (auth: L), K (auth: M), L (auth: N)
Chain Length:219
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:3301 Fab Heavy Chain
Chain IDs:M (auth: O), O (auth: Q), Q (auth: S)
Chain Length:231
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:3301 Fab Light Chain
Chain IDs:N (auth: P), P (auth: R), R (auth: T)
Chain Length:214
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

The traditional process of antibody discovery is limited by inefficiency, high costs, and low success rates. Recent approaches employing artificial intelligence (AI) have been developed to optimize existing antibodies and generate antibody sequences in a target-agnostic manner. In this work, we present MAGE (monoclonal antibody generator), a sequence-based protein language model (PLM) fine-tuned for the task of generating paired human variable heavy- and light-chain antibody sequences against targets of interest. We show that MAGE can generate novel and diverse antibody sequences with experimentally validated binding specificity against SARS-CoV-2, an emerging avian influenza H5N1, and respiratory syncytial virus A (RSV-A). MAGE represents a first-in-class model capable of designing human antibodies against multiple targets with no starting template.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback